New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePNC-27 vs Humanin

PNC-27 vs Humanin

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PNC-27
Anti-Aging & Longevity
Humanin
Summary
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
Half-Life
Not well established; estimated minutes to hours
~4–8 hours (HNG)
Admin Route
Intravenous (research), Intraperitoneal (research)
SubQ
Research
Typical Dose
Not established for humans; research doses vary by cell line and model
2–8 mg
Frequency
Not established for human use
3–5 times per week
Key Benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
  • Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
  • Inhibits cellular apoptosis
  • Improves insulin sensitivity
  • Reduces cardiovascular risk markers
  • Anti-inflammatory effects
  • Correlates with longevity in centenarian studies
  • Protects against ischemic injury
  • Potential cancer cell apoptosis sensitization
Side Effects
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
  • Injection site irritation
  • Limited human safety data available
Stacks With